Showing results (131-140 of 154) with videos related to
Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.Blood Advances|October 5, 2019
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cellsJohan Jeong, Astraea Jager, Pablo Domizi, et al.Blood|August 28, 2015
MLL leukemia induction by genome editing of human CD34+ hematopoietic cellsCorina Buechele, Erin H Breese, Dominik Schneidawind, et al.Cancer Cell|April 25, 2025
Stromal lipid species dictate melanoma metastasis and tropismShilpa Gurung, Timothy Budden, Karthik Mallela, et al.Cancer Cell|September 24, 2013
Epigenetic roles of MLL oncoproteins are dependent on NF-κBHsu-Ping Kuo, Zhong Wang, Dung-Fang Lee, et al.Journal of Medicinal Chemistry|December 23, 2016
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia CellsStuart Jones, Jonathan Ahmet, Kelly Ayton, et al.Blood|November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.Cancer Gene Therapy|July 6, 2022
Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemiaPatricia K Grüninger, Franziska Uhl, Heike Herzog, et al.Cell Stem Cell|April 30, 2019
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid LeukemiaJasmin Paris, Marcos Morgan, Joana Campos, et al.Gene Therapy|July 25, 2020
Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cellsToshinobu Nishimura, Haojun Xu, Masayuki Iwasaki, et al.Pageof 16